Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS

Journal of the National Cancer Institute

Volumn 103, Issue 6, 2011, Pages 478-488

  Wapnir, Irene L ^a,b   Dignam, James J ^a,c   Fisher, Bernard ^d   Mamounas, Eleftherios P ^a,e   Anderson, Stewart J ^a,f   Julian, Thomas B ^a,g   Land, Stephanie R ^a,f   Margolese, Richard G ^a,h   Swain, Sandra M ⁱ   Costantino, Joseph P ^a,f   Wolmark, Norman ^a,g  

^a NSABP Foundation Inc   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^g ALLEGHENY GENERAL HOSPITAL   (United States)

^h MCGILL UNIVERSITY   (Canada)

ⁱ WASHINGTON CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TAMOXIFEN;

ADULT; AGED; ARTICLE; ATTRIBUTABLE RISK; BREAST CANCER; BREAST TUMOR; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER INVASION; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EXAMINATION; CONTRALATERAL BREAST CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; EVENT FREE SURVIVAL; FEMALE; HAZARD RATIO; HUMAN; INTRADUCTAL CARCINOMA; INVASIVE IPSILATERAL BREAST TUMOR RECURRENCE; IPSILATERAL BREAST TUMOR RECURRENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MAMMOGRAPHY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CHEMOTHERAPY, ADJUVANT; CONFOUNDING FACTORS (EPIDEMIOLOGY); DOUBLE-BLIND METHOD; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ODDS RATIO; PROGNOSIS; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 79952845819     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr027     Document Type: Article

References (44)

1. Li CI, Daling JR, Malone KE. Age-specifc incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001. Cancer Epidemiol Biomarkers Prev. 2005;14(4):1008-1011. (Pubitemid 40478573)
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57(1):43-66. (Pubitemid 46148091)
3. Veronessi U, Sacozzi R, del Vecchio M, et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med. 1981;305(1): 6-11. (Pubitemid 11071189)
4. Fisher B, Bauer M, Margolese R, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med. 1985; 312(11):665-673. (Pubitemid 15134702)
5. Betsill WL Jr, Rosen PP, Lieberman PH, Robbins GF. Intraductal carcinoma. Long term follow-up after treatment by biopsy alone. JAMA. 1978; 239(18):1863-1867. (Pubitemid 8322874)
6. Page DL, Dupont WD, Rogers LW, Landenberger M. Intraductal carcinoma of the breast. Follow-up after biopsy only. Cancer. 1982;49(4): 751-758. (Pubitemid 12165434)
7. Lagios MD, Westdahl PR, Margolin FR, Roses MR. Ductal carcinoma in situ. Relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures. Cancer. 1982;50(7):1309-1314. (Pubitemid 12031954)
8. Montague ED. Conservation surgery and radiation therapy in the treatment of operable breast cancer. Cancer. 1984;53(3 suppl):700-704. (Pubitemid 14190895)
9. Recht A, Danoff BS, Solin LJ, et al. Intraductal carcinoma of the breast: results of treatment with excisional biopsy and irradiation. J Clin Oncol. 1985;3(10):1339-1343.
10. Rosner D, Bedwani R, Vana J, Baker H, Murphy G. Noninvasive carcinoma breast, results of a national survey by the American College of Surgeons. Ann Surg. 1980;192(2):139-147. (Pubitemid 10034330)
11. Fisher ER, Sass R, Fisher B, Wickerham L, Paik SM. Pathologic fndings from the National Surgical Adjuvant Breast Project (Protocol 6).I. Intraductalcarcinoma (DCIS). Cancer. 1986;57(2):197-208. (Pubitemid 16212019)
12. Fisher B, Costantino J, Redmond C, et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med. 1993;328(22):1581-1586. (Pubitemid 23151917)
13. Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: fndings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998;16(2):441-452. (Pubitemid 28135585)
14. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intra-ductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353(9169):1993-2000. (Pubitemid 29271743)
15. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol. 2001;28(4):400-418. (Pubitemid 32762083)
16. Romero L, Klein L, Ye W, et al. Outcome after invasive recurrence in patients with ductal carcinoma in situ of the breast. Am J Surg. 2004;188(4):371-376. (Pubitemid 39330538)
17. Li CI, Malone KE, Saltzman BS, Daling JR. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001. Cancer. 2006;106(10):2104-2112. (Pubitemid 43673230)
18. Fisher ER, Costantino JP, Fisher B, et al. Pathologic fndings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Five-year observations concerning lobular carcinoma in situ. Cancer. 1996;78(7):1403-1416. (Pubitemid 26317860)
19. Julian TB, Land SR, Wang Y, Vicini FA, Arthur DW, Wolmark N. National Surgical Adjuvant Breast and Bowel Project. Is boost therapy necessary in the treatment of DCIS? ASCO Breast Cancer Symposium. 2007. Abstract 146.
20. Prentice RL, Kalbfeisch JD, Peterson AV Jr., Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics. 1978;34(4):541-554. (Pubitemid 9067879)
21. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 1982;69(1):239-241.
22. Korn EL, Dorey FJ. Applications of crude incidence curves. Stat Med. 1992;11(6):813-829.
23. Fisher ER, Costantino J, Fisher B, Palekar AS, Redmond C, Mamounas E. Pathologic fndings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Intraductal carcinoma (ductal carcinoma in situ). The National Surgical Adjuvant Breast and Bowel Project Collaborating Investigators. Cancer. 1995;75(6):1310-1319.
24. Fisher ER, Dignam J, Tan-Chiu E, et al. Pathologic fndings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer. 1999;86(3):429-438. (Pubitemid 29347405)
25. Fisher ER, Land SR, Saad RS, et al. Pathologic variables predictive of breast events in patients with ductal carcinoma in situ. Am J Clin Pathol. 2007;128(1):86-91, p.7S. (Pubitemid 47121719)
26. Ibrahim MN, Abdullah Z, Healy L, Murphy C, Yousif IY, Martin MJ. Comparison. of survival rates in carcinoma in situ of the breast treated with total mastectomy to breast-conserving surgery and radiotherapy. ASCO Ann Meet Proc Part I. 2007;25(18 S) (Suppl) Abstract 519, p 7S.
27. Rakovitch E, Pignol JP, Chartier C, et al. The management of ductal carcinoma in situ of the breast: a screened population-based analysis. Breast Cancer Res Treat. 2007;101(3):335-347. (Pubitemid 46169888)
28. Innos K, Horn-Ross PL. Risk of second primary breast cancers among women with ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2008;111(3):531-540.
29. Bijker N, Meijnen P, Peterse JL, et al. Breast conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853-a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006;24(21):3381-3387. (Pubitemid 46638893)
30. Holmberg L, Garmo H, Granstrand B, et al. Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol. 2008;26(8):1247-1252.
31. Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 2003;362(9378):95-102. (Pubitemid 36831018)
32. Cuzick J, Sestak I, Pinder S, et al. Benefcial effect of tamoxifen for women with DCIS: long-term results from the UK/ANZ DCIS Trial in women with locally excised DCIS. Cancer Res. 2009;69(24 suppl) Abstract 34.
33. Schairer C, Mink PJ, Carroll L, Devesa SS. Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst. 2004;96(17):1311-1321. (Pubitemid 39264120)
34. Ernster VL, Barclay J, Kerlikowske K, Wilkie H, Ballard-Barbash R. Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med. 2000;160(7):953-958. (Pubitemid 30191923)
35. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320(8):479-484. (Pubitemid 19062522)
36. Wapnir I, Anderson S, Mamounas E, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional failure in fve National Surgical Adjuvant Breast and Bowl Project node-positive adjuvant breast cancer trials. J Clin Oncol. 2006;24(13):2028-2037. (Pubitemid 46622111)
37. Anderson S, Wapnir I, Dignam J, et al. Prognosis after IBTR and locore-gional recurrences treated by breast-conserving surgery in fve NSABP node-negative breast cancer protocols. J Clin Oncol. 2009;27(15):2466-2473.
38. Wong JS, Kaelin CM, Troyan SL, et al. Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol. 2006;24(7): 1031-1036. (Pubitemid 46638798)
39. Hughes LL, Wang M, Page DL, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27(32): 5319-5324.
40. Allred DC, Bryant J, Land S, et al. Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: fndings from NSABP protocol B-24. San Antonio Breast Cancer Symposium. Breast Cancer Res Treat. 2002;76(suppl 1):536. Abstract 30.
41. Altekruse SF, Kosary CL, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute; 2010. http://seer.cancer.gov/csr/1975-2007/sections.html, Accessed February 4, 2011.
42. NSABP B-35. A clinical trial comparing anastrazole with tamoxifen in postmenopausal patients with DCIS undergoing lumpectomy with radiation therapy: http://www.clinicaltrials.gov/ct2/show/NCT00053898. Accessed February 4, 2011.
43. NSABP B-39 A randomized phase III study of conventional whole breast irradiation vs. partial breast irradiation for women with stage 0, I, or II breast cancer: http://www.clinicaltrials.gov/ct/show/NCT00103181. Accessed Feburary 4, 2011.
44. NSABP B-43. A phase III trial comparing trastuzumab given concurrently with radiation therapy and radiation therapy alone for women with HER-2 positive DCIS resected by lumpectomy: http://www.clinicaltrials. gov/ct2/show/ NCT00769379. Accessed February 4, 2011.